Clinical trials: Blood Tests
Healthy Volunteers
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
- Trial name
- NCT01758432
- Testing
- PRT064445/Apixaban
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Clostridium Difficile Infection, Hematologic Diseases
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
This study will randomized hematology oncology patients with active diarrhea and a NAAT positive/toxin EIA negative to either 14 days of oral vancomycin capsules or placebo.
- Conditions
- Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
- Trial name
- NCT03030248
- Testing
- Vancomycin Oral Capsule
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical College of Wisconsin
Bloodstream Infection, Sepsis Bacterial
Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Bacterial blood stream infections are common and life-threatening. Bloodstream infections have historically been identified using blood cultures, which often take 24-72 hours to result and are imperfectly sensitive.
- Conditions
- Bloodstream Infection, Sepsis Bacterial, MRSA Bacteremia, Vancomycin
- Trial name
- NCT06069206
- Testing
- T2Bacteria® Panel (direct-from-blood testing), Usual Care
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Vanderbilt University Medical Center
Healthy
A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
In order to assess the potential impact of steady state BI 425809 on CYP3A clinically, the effect of BI 425809 on the midazolam pharmacokinetics will be evaluated. Midazolam is a recommended substrate of CYP3A4.
- Trial name
- NCT05258110
- Testing
- midazolam, iclepertin (BI 425809)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Attention Deficit Hyperactivity Disorder (ADHD)
Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
The purpose of this research study is to learn about the effects of a medication called Vyvanse on the heart (cardiovascular system). The U.S.
- Trial name
- NCT00753012
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus
A New Glucose Meter With Alternative Site Testing
The purpose of the study was to evaluate the performance of the blood glucose monitoring system when used with samples taken from the palm and forearm for alternative site testing (AST).
- Trial name
- NCT00797212
- Testing
- Apollo Blood Glucose Monitoring System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ascensia Diabetes Care
Kidney Failure, Chronic, Growth Hormone Deficiency
A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
Treatment with growth hormone (GH; a hormone made by the body that stimulates growth) has been shown to be helpful in treating children with chronic kidney disease who fail to grow.
- Trial name
- NCT00212758
- Testing
- Nutropin AQ
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oregon Health and Science University
Acute Myeloid Leukemia
A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists
The objective of this study is to evaluate the preliminary efficacy of the UR-GOAL tool in improving shared decision making and communication between older patients with AML and their oncologists in a pilot randomized trial.
- Trial name
- UR-GOAL 2 (NCT05335369)
- Testing
- UR-GOAL
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- University of Rochester
Healthy
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood
The primary objective of this trial is to investigate the safety and tolerability of BI 1358894 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03210272
- Testing
- BI 1358894, BI 1358894 (Test), BI 1358894 (Reference)
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV Infections
Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid
This protocol is intended to test the feasibility of using the HIV 1/2 STAT-PAK and the DPP HIV 1/2 test (with and without the DPP Handheld Reader) to detect HIV antibodies in oral fluids.
- Trial name
- HIVOF (NCT00636220)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Chembio Diagnostic Systems, Inc.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439227
- Testing
- Adavosertib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood
The main objective of this trial is to investigate the induction effect of multiple doses of BI 1015550 on the pharmacokinetics of the sensitive CYP3A4 substrate midazolam.
- Trial name
- NCT05550636
- Testing
- BI 1015550, midazolam
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hiv
CHALO! 2.0: A Mobile Technology Based Intervention to Accelerate HIV Testing and Linkage to Preventive Treatment.
While HIV prevalence among Men Seeking Men (MSM) in India is 10-15 times higher than in the general population (4.3% vs 0.3%), current interventions for Indian MSM have limited reach.
- Trial name
- NCT04814654
- Testing
- CHALO! 2.0, Attention-matched control (AMC), Digital coupon only (DCO)
- Where
- India
- Volunteers
- 1,004 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Diabetes
Continuous Glucose Monitoring in Critically Ill
The goal of this clinical research study is to learn if The Guardian® blood-sugar monitoring device can be used reliably in patients with high blood sugar who are receiving care in the ICU.
- Trial name
- NCT00707434
- Testing
- Guardian® blood-sugar monitoring device
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone…
- Trial name
- POM MM 014 (NCT01946477)
- Testing
- Pomalidomide, Dexamethasone, Daratumumab
- Where
- 49 sites in United States, Canada and 2 more
- Volunteers
- 186 people
- Sponsor
- Celgene
Plasmacytoma, Recurrent Multiple Myeloma
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or…
- Conditions
- Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT03031730
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood
BI 1810631 trial formulation 1 (TF1) is currently used in clinical trials, but is planned to be replaced by another formulation (principle) in future clinical trials and on the market.
- Trial name
- NCT05380947
- Testing
- BI 1810631 - trial formulation 1 (TF1), BI 1810631 - new formulation (NF), Rabeprazole sodium
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Immunologic Tests
A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays
The purpose of this study is to develop and characterize immunological assays on blood samples.
- Trial name
- NCT01098006
- Testing
- Blood withdrawal
- Where
- 2 sites in Belgium
- Volunteers
- 99 people
- Sponsor
- GlaxoSmithKline
HIV Infections, Sexually Transmitted Diseases, Viral
mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention
Men who have sex with men (MSM), especially young men who have sex with men (YMSM), and transgender women (TGW) have some of the highest rates of HIV and syphilis diagnoses in the United States.
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Viral, Syphilis
- Trial name
- NCT06059443
- Testing
- mLab App Plus
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Columbia University
Malignant Neoplasm of Large Intestine
Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population
The purpose of this study is to determine if the direct mailing of fecal occult blood testing (FOBT) kits to patients who are due for colorectal cancer screening is an effective way to improve colorectal cancer screening rates…
- Trial name
- NCT01385579
- Testing
- Care manager outreach
- Where
- United States
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Northwestern University